Status Plus

abstract

abstract

561

Analysis of unsuccessful treatment of lifelong premature ejaculation with dapoxetine

Guo, J1; Wang, F1; Geng, Q2; Gao, QH3; Han, Q4; Yan, B3; Zhang, JW3; Zhang, XJ3; Yu, GJ3; Zeng, Y3; Liu, Y3

1: Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing,China; 2: The First Affiliated Hospital of Tianjin University of Traditional Chinese Medicine,Tianjin ,China.; 3: Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing,China; 4: Beijing Hospital of Traditional Chinese Medicine

Dapoxetine is the initial treatment option for lifelong premature ejaculation(LPE). Nevertheless, unsuccessful treatment rates of up to 15-30 % have been reported. This study presents the analysis of failure and clinical outcome of LPE with dapoxetine.

Objective:To discuss the unsuccessful reasons LPE with dapoxetine and the preventive methods of the unsuccessful clinic cases to dapoxetine

Methods:The retrospective analysis was carried on 30 LPE patients from April 2016 to July 2017 who were suffered from lifelong premature ejaculation with unsuccessful results . Pre-assessment included history , physical examination, diagnostic measure (Premature Ejaculation DiagnosticTool [PEDT]),and Psychological Factors.

Results:The average age at the time of LPE was 32.52 years (range, 18-55 years). Three main reasons for failure after treatment could be identified: failure to consider course of treatment(12/30), psychological problems, particularly severe anxiety(9/30), not enough doses(4/30);The rest of unrealistic patient expectations (4/30) ,other (1/30).

Conclusion:It is necessary to select course ,dose and psychological counseling for preventing the occurring of the unsuccessful results. Treatment failures might be due to the severity of the underlying pathophysiology, improper use of medication, unrealistic patient expectations, severe performance anxiety, and other psychological problems. Physicians must address these issues to identify true treatment failures attributable to the dapoxetine.

Disclosure:

Work supported by industry: no.

Go Back